Alimera Sciences, Inc. (NASDAQ:ALIM) has received a consensus broker rating score of 1.00 (Strong Buy) from the two analysts that provide coverage for the company, Zacks Investment Research reports. Two analysts have rated the stock with a strong buy recommendation.

Brokers have set a 12 month consensus target price of $4.00 for the company and are predicting that the company will post ($0.03) EPS for the current quarter, according to Zacks. Zacks has also assigned Alimera Sciences an industry rank of 114 out of 265 based on the ratings given to its competitors.

Several analysts have commented on ALIM shares. Cowen and Company set a $3.00 target price on shares of Alimera Sciences and gave the company a “buy” rating in a research report on Tuesday, July 25th. HC Wainwright set a $5.00 target price on shares of Alimera Sciences and gave the company a “buy” rating in a research report on Wednesday, July 26th. Zacks Investment Research upgraded shares of Alimera Sciences from a “sell” rating to a “hold” rating in a research report on Friday, September 8th. Finally, ValuEngine cut shares of Alimera Sciences from a “hold” rating to a “sell” rating in a research report on Thursday, July 27th.

Several institutional investors and hedge funds have recently added to or reduced their stakes in ALIM. KCG Holdings Inc. increased its position in shares of Alimera Sciences by 127.0% in the 1st quarter. KCG Holdings Inc. now owns 78,604 shares of the biopharmaceutical company’s stock valued at $110,000 after buying an additional 43,977 shares in the last quarter. PNC Financial Services Group Inc. increased its position in shares of Alimera Sciences by 24.3% in the 2nd quarter. PNC Financial Services Group Inc. now owns 180,300 shares of the biopharmaceutical company’s stock valued at $251,000 after buying an additional 35,200 shares in the last quarter. Stonepine Capital Management LLC increased its position in shares of Alimera Sciences by 158.2% in the 3rd quarter. Stonepine Capital Management LLC now owns 477,226 shares of the biopharmaceutical company’s stock valued at $644,000 after buying an additional 292,399 shares in the last quarter. Finally, JW Asset Management LLC increased its position in shares of Alimera Sciences by 15.6% in the 2nd quarter. JW Asset Management LLC now owns 966,000 shares of the biopharmaceutical company’s stock valued at $1,343,000 after buying an additional 130,000 shares in the last quarter. Institutional investors and hedge funds own 36.82% of the company’s stock.

Shares of Alimera Sciences (NASDAQ ALIM) remained flat at $$1.25 during trading on Tuesday. 54,200 shares of the company’s stock traded hands, compared to its average volume of 390,230. Alimera Sciences has a twelve month low of $1.04 and a twelve month high of $1.72. The company has a current ratio of 4.84, a quick ratio of 4.65 and a debt-to-equity ratio of -0.71.

TRADEMARK VIOLATION NOTICE: “Zacks: Alimera Sciences, Inc. (ALIM) Given Average Recommendation of “Strong Buy” by Brokerages” was first posted by American Banking News and is owned by of American Banking News. If you are reading this piece on another domain, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The original version of this piece can be read at https://www.americanbankingnews.com/2017/11/14/zacks-alimera-sciences-inc-alim-given-average-recommendation-of-strong-buy-by-brokerages.html.

About Alimera Sciences

Alimera Sciences, Inc (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina.

Get a free copy of the Zacks research report on Alimera Sciences (ALIM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Alimera Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.